Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Severe alcohol use disorder~* High-risk alcohol consumption~Exclusion Criteria:~* Patient with orthostatic hypotension~* Patient with hypotension~* History of uncontrolled hypertension~* Patient at risk for urinary retention associated with urethroprostatic disorders~* Patient with a clinically-active malignancy~* Patient with a confirmed cirrhosis~* History of bronchial asthma~* History of uncontrolled hyperthyroidism~* History of cardiovascular disease not under control~* Severe psychiatric disorder~* History of alcohol withdrawal syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low-dose group (Type: EXPERIMENTAL): Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).
- High-dose group (Type: EXPERIMENTAL): Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg \[2 tablets of 5 mg\] once a day slow-release: evening administration)
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)

Based on this trial design, predict the completion outcome and termination type (if applicable).